Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.

about

Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.

Item

http://www.wikidata.org/entity/Q38639456

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Incidence and identification o ...... a single "real-world" setting.

@en

type

Item

label

Incidence and identification o ...... a single "real-world" setting.

@en

prefLabel

Incidence and identification o ...... a single "real-world" setting.

@en

P1476

Incidence and identification o ...... a single "real-world" setting

@en

P2093

Andrew T Yan

http://www.w3.org/2001/XMLSchema#string

Christine Brezden-Masley

http://www.w3.org/2001/XMLSchema#string

Laura Sevick

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Peginesatide in patients with anemia undergoing hemodialysis.

Adjuvant trastuzumab in HER2-positive breast cancer.

Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study.

Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.

P2888

s12032-017-1018-y

P304

154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-017-1018-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sergio A Acuna

Grace H Tang

P577

2017-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090994345

http://www.w3.org/2001/XMLSchema#string

P698

28779423

http://www.w3.org/2001/XMLSchema#string